[HTML][HTML] Thyroglobulin as a tumor marker in differentiated thyroid cancer–clinical considerations

M Prpić, M Franceschi, M Romić, T Jukić… - Acta Clinica …, 2018 - ncbi.nlm.nih.gov
Initial treatment of the majority of patients with differentiated thyroid cancer (DTC) includes
total thyroidectomy. Postoperative ablation therapy with radioactive iodine (I-131) is …

Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

A Piccardo, M Puntoni, G Ferrarazzo, L Foppiani… - European journal of …, 2018 - Springer
Purpose Current guidelines recommend thyroid hormone withdrawal (THW) of 3–4 weeks
before radioiodine remnant ablation (RRA) of differentiated thyroid carcinoma (DTC). We …

[PDF][PDF] 目前对分化型甲状腺癌患者放射性碘治疗准备工作主要方面的看法: 文献综述

MV Reinberg, KY Slashchuk, AA Trukhin… - Digital …, 2023 - jdigitaldiagnostics.com
АННОТАЦИЯ Рак щитовидной железы—наиболее распространённая опухоль
эндокринной системы, составляющая 1–3% всех злокачественных новообразований …

[HTML][HTML] Preparation for radioiodine therapy in patients with differentiated thyroid cancer, modern perspective. Review of the literature.

MV Ryzhenko, KY Slashchuk, AA Trukhin… - Digital …, 2023 - jdigitaldiagnostics.com
Thyroid cancer is the most common tumor of the endocrine system, 1-3% of all malignant
neoplasms as of 2021. Differentiated forms, papillary and follicular, with a relatively …

[PDF][PDF] Современный взгляд на основные аспекты подготовки пациентов с дифференцированным раком щитовидной железы к радиойодтерапии: научный …

МВ Рейнберг, КЮ Слащук, АА Трухин… - Digital …, 2023 - jdigitaldiagnostics.com
АННОТАЦИЯ Рак щитовидной железы—наиболее распространённая опухоль
эндокринной системы, составляющая 1–3% всех злокачественных новообразований …

Interrupted 131I procedures for patients with differentiated thyroid cancer: comparing thyroxine withdrawal with recombinant thyrotropin preparation techniques

S Karls, G Abikhzer, M Tamilia… - Clinical Nuclear Medicine, 2017 - journals.lww.com
Objective In patients with differentiated thyroid carcinoma scheduled to receive doses of 131
I for diagnostic or therapeutic purposes, we compared patients prepared with thyroid …

Análise dos fatores preditores de malignidade em nódulos tireoidianos submetidos a tireoidectomia ea correlação com os sistemas de classificação diagnóstica: um …

GH Webber, GC Lessack… - Journal …, 2023 - ojs.latinamericanpublicacoes.com.br
Introdução: o manejo das neoplasias de tireoide é muitas vezes difícil pela incerteza do
risco de malignidade. Quando suspeita-se de um nódulo tireoidiano, exames …

Tireoglobulin: tumorski biljeg diferenciranih karcinoma štitnjače-klinička razmatranja

M Prpić, M Franceschi, M Romić, T Jukić… - Acta clinica Croatica, 2018 - hrcak.srce.hr
Sažetak Početno liječenje većine bolesnika s diferenciranim karcinomom štitnjače uključuje
kirurško odstranjenje štitnjače. Poslijeoperacijsko liječenje radioaktivnim jodom (I-131) …

Comparação do perfil lipídico de pacientes tireoidectomizados em hipo e eutireoidismo

AC FREITAS - 2018 - repositorio.ufpe.br
A dislipidemia é o fator de risco mais bem compreendido e estabelecido para a
aterosclerose-principal responsável pelas doenças cardiovasculares (DCV), que são a …

[引用][C] Preparation for radioiodine therapy in patients with differentiated thyroid cancer: a modern perspective (a review)

MV Reinberg, KY Slashchuk, AA Trukhin… - Digital …, 2023 - jdigitaldiagnostics.com